Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 5, 2011, Pages 907-913

  Mücke, Thomas ^a   Koschinski, Janett ^a   Deppe, Herbert ^a   Wagenpfeil, Stefan ^a   Pautke, Christoph ^a   Mitchell, David A ^b   Wolff, Klaus Dietrich ^a   Hölzle, Frank ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Bisphosphonates; Jaws; Osteonecrosis; Recurrence; Surgery; Treatment outcome

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; HEXETIDINE; IBANDRONIC ACID; PENICILLIN G; ZOLEDRONIC ACID;

ACTINOMYCOSIS; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIUM DETECTION; BONE GRAFT; BONE INFECTION; BONE NECROSIS; BREAST CANCER; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DEBRIDEMENT; HUMAN; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MAXILLA OSTEOTOMY; MULTIPLE MYELOMA; ORTHOPEDIC SURGERY; OSTEOLYSIS; OSTEOPOROSIS; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME;

ACTINOMYCES; AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW DISEASES; MIDDLE AGED; OSTEONECROSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 79955692119     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0953-1     Document Type: Article

References (36)

1. AAOMS (2007) American association of oral and maxillofacial surgeon's position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369
2. Abu-Id MH, Acil Y, Gottschalk J, Kreusch T (2006) Bisphosphonate- associated osteonecrosis of the jaw. Mund Kiefer Gesichtschir 10:73
3. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945
4. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, Zervas K, Baer MR, Meiller T, Dimopoulos MA (2008) Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 26:5904
5. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580
6. Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, Tregnaghi A, Pietrogrande F, Procopio O, Saia G, Ferretti M, Bedogni G, Chiarini L, Ferronato G, Ninfo V, Lo Russo L, Lo Muzio L, Nocini PF (2008) Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105:358
7. Body JJ (2006) Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 12:6258s
8. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857
9. Carlson ER, Basile JD (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:85
10. Conte PF, Giannessi PG, Latreille J, Mauriac L, Koliren L, Calabresi F, Ford JM (1994) Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol 5(Suppl 7):S41
11. Engroff SL, Kim DD (2007) Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction? J Oral Maxillofac Surg 65:2374
12. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, Piantadosi CA (2007) Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 65:1321
13. Greenberg MS (2004) Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:259
14. Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155
15. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, Patrikidou A, Triaridis S (2008) Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 26:4634
16. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115
17. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate- induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567
18. Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397
19. Migliorati CA (2003) Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253
20. Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104:83
21. Mücke T, Haarmann S, Wolff KD, Hölzle F (2009) Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction. J Craniomaxillofac Surg 37:291
22. Nocini PF, Saia G, Bettini G, Ragazzo M, Blandamura S, Chiarini L, Bedogni A (2009) Vascularized fibula flap reconstruction of the mandible in bisphosphonate-related osteonecrosis. Eur J Surg Oncol 35:373
23. Pautke C, Bauer F, Tischer T, Kreutzer K, Weitz J, Kesting M, Holzle F, Kolk A, Sturzenbaum SR, Wolff KD (2009) Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:471
24. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527
25. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E (2010a) Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate- associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 14:311
26. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, Neukam FW, Nkenke E (2010b) Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 18:449
27. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, Hughes PJ, Michalowicz BS, Leach JW, Swenson KK, Swift JQ, Adkinson C, Basi DL (2009) Bisphosphonate- related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 67:1904
28. Vasikaran SD (2001) Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38:608
29. Vescovi P, Merigo E, Meleti M, Manfredi M (2006) Bisphosphonate- associated osteonecrosis (BON) of the jaws: a possible treatment? J Oral Maxillofac Surg 64:1460
30. Vescovi P, Manfredi M, Merigo E, Meleti M (2008) Early surgical approach preferable to medical therapy for bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 66:831
31. Vogel F, Scholz H, al-Nawas B, Elies W, Kresken M, Lode H, Muller O, Naber KG, Petersen E, Shah P, Sorgel F, Stille W, Tauchnitz C, Trautmann M, Ullmann U, Wacha H, Wiedemann B (2002) Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich society for chemotherapy. Med Monatsschr Pharm 25:193
32. Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066
33. Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104
34. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ (2007) Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65:1328
35. Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753
36. Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A (2006) Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 118:473